Knee osteoarthritis is a degenerative joint disease that causes pain, swelling, and stiffness and can progressively impair mobility. It is the most commonly affected osteoarthritis site globally.
NEXT BIOMEDICAL completed an FDA pre-submission review for Nexsphere-F under the TAP program. NexEos Bio received IND clearance to begin a Phase II/III trial of NTX-1024 for vernal keratoconjunctivitis, supported by positive early clinical data.
MEDIPOST treated the first U.S. participant in a Phase III trial of its umbilical cord blood-derived MSC therapy for knee osteoarthritis. The FDA agreed the single pivotal study, supported by prior trials in South Korea and Japan, can support a planned BLA filing.
Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.
Roche signed an agreement to invest $478 million in Korea clinical trials over five years, marking the largest foreign pharmaceutical investment. Korean companies are also securing pre-approval licensing deals globally, demonstrating growing competitiveness.
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
GLP-1 weight loss drugs show increasing efficacy but raise concerns about excessive weight loss, side effects, and the rise of unregulated compounded versions sold online.
MEDIPOST has submitted an investigational new drug amendment to the FDA to initiate a Phase III trial of its umbilical cord blood-derived mesenchymal stem cell therapy for knee osteoarthritis, with patient enrollment expected in the first half of 2026.
Eli Lilly reported positive Phase 3 results for retatrutide showing up to 71.2 lbs average weight loss, while stockpiling $1.5 billion of oral drug orforglipron ahead of anticipated FDA approval in April 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779122 |
Wearable Electrogoniometry-Based Telerehabilitation After Total Knee Arthroplasty |
COMPLETED | NA |
| NCT07774195 |
Efficacy of AI-Driven and Traditional Physical Therapy Programs in Patients With Knee Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07773480 |
Formative Evaluation of a Mobile Application Facilitated Self-directed Rehabilitation Programme for Knee Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07769593 |
MORA Cure for Knee Osteoarthritis With Anterior Knee Pain |
ACTIVE_NOT_RECRUITING | NA |
| NCT07754175 |
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial |
RECRUITING | |
| NCT07744789 |
Knee Ligament Stiffness Across Ethnicities Before and After Osteoarthritis Treatment |
RECRUITING | |
| NCT07741162 |
Paraspinal NMES and Spinopelvic Alignment After Knee Arthroplasty |
NOT_YET_RECRUITING | NA |
| NCT07739108 |
Suprainguinal Fascia Iliaca Block vs. Adductor Canal Block for Analgesia After Total Knee Arthroplasty |
NOT_YET_RECRUITING | NA |
| NCT07738627 |
Effects of IMT on Cardiopulmonary Endurance and Functional Mobility in KOA |
NOT_YET_RECRUITING | NA |
| NCT07736352 |
Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants. |
NOT_YET_RECRUITING | NA |
